CureMatch
×
  • Physicians
  • BioPharma
  • Employers
  • News
  • Clinical Order
  • About Us
  • Login

Personalized Drug Combinations More Effective than Current Standard of Care for Pancreatic Cancer

Personalized Drug Combinations More Effective than Current Standard of Care for Pancreatic Cancer
PublicationsValidation

New study published in ANTICANCER RESEARCH Journal offers potential proof-of-concept for precision medicine approach to cancer treatment.

SAN DIEGO, CA – April 12, 2018:  A new in vitro cancer study supports the concept of matched combination therapies as more effective treatment when compared to matched monotherapies or the current standard of care. Among the most frequently used anticancer drugs, of which there are around 300, very few combinations have actually been explored in clinical trials. Thus, experimental validation of combination therapies simultaneously targeting several mutated genes is an important step in the progression of the field.

The study explored the effects of a combinatorial therapy on cancer cell lines bearing specific mutational profiles in pancreatic cancer, specifically ductal adenocarcinoma (PDAC), the fourth most common cause of cancer-related death. The current standard treatment for advanced PDAC has not shown a significantly improved survival rate in over four decades, clearly indicating the need to develop new treatments for this disease.

Recent advances in genomics analysis, the quantification and characterization of genes which direct the production of proteins (molecules that do most of the work in cells), now allows for the selection of anti-cancer drugs specifically matched to genomic alterations found in a patient’s cancer. The study focused on a PDAC cell line, CAPAN2, originating from a human pancreatic adenocarcinoma primary tumor. In this cell line, there are specific functionally altering mutations in the proteins, ABL1 (a tyrosine kinase involved in the regulation a number of cellular processes) and KRAS (a small GTPase which is part of RAS/MAPK signaling pathway). The study shows that drugs, regorafenib (RTK inhibitor) and trametinib (MEK inhibitor), individually and in combination, significantly reduced the proliferation of these pancreatic cancer cells in vitro.

More significantly, combinations of these two anti-cancer drugs were found to have synergistic effects. In general, if a drug pair/combination improves the inhibitory potency relative to that of each drug alone, the combination is considered synergistic; if potency remains unchanged, the effect is considered additive; and if potency is reduced, the effect is considered antagonistic. The study showed that trametinib and regorafenib combined in specific ratios of concentrations were found to lead to increased cancer cell death at much lower concentrations than either of the drugs in monotherapy.

Personalized combination therapy is rapidly becoming a highly promising option for the treatment of cancer. It is believed that combinations of anti-cancer therapies matched to the actionable cancer genomic profile of a patient would likely result in better response. However, due to limited experimental justification for the use of personalized combination therapy, most cancer patients are still routinely treated with the so-called standard of care which does not typically take into account genetic aberrations found in cancer. This is particularly unfortunate given the recent explosion of genomic research as well as drug design and development.

Researchers and clinicians have the unique opportunity to treat cancer as a truly personal disease. Intelligent computing systems can streamline the daunting task of selecting the most promising combinations of anticancer drugs for each patient. CureMatch® is a digital precision oncology company bridging the gap between legacy cancer treatments and advances in personalized medicine. In PreciGENE reports, CureMatch scores and ranks Personalized Combination Therapy® options to target specific molecular aberrations and improve the precision of cancer treatment recommendations.

The study, “In Vitro Elucidation of Drug Combination Synergy in Treatment of Pancreatic Ductal Adenocarcinoma” in ANTICANCER RESEARCH1 is authored by Kevin T. Bush, Ph.D., Amelie Boichard, Ph.D., and Igor F. Tsigelny, Ph.D.

###

Journal Reference

[1] In Vitro Elucidation of Drug Combination Synergy in Treatment of Pancreatic Ductal Adenocarcinoma

Kevin T. Bush 1,2*, Amelie Boichard 3*, Igor F. Tsigelny 1,4

1 CureMatch Inc., San Diego, CA, U.S.A.; 2 Department of Pediatrics, University of California San Diego, La Jolla, CA, U.S.A.; 3 Center for Personalized Cancer Therapy, University of California San Diego, Moores Cancer Center, La Jolla, CA, U.S.A.; 4 Super-Computer Center San Diego, La Jolla, CA, U.S.A.

ANTICANCER RESEARCH vol. 38 no. 4 1967-1977 (April 2018) doi :10.21873/anti canres.11xxx  A

http://ar.iiarjournals.org/content/38/4/1967.abstract?sid=01ee5948-770a-46b9-ada5-638f77ff93df

About ANTICANCER RESEARCH Journal
ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. ANTICANCER RESEARCH was established in 1981 and is published monthly.

About CureMatch®
CureMatch, Inc. is a digital precision oncology company bridging the gap between legacy cancer treatments and advances in personalized medicine. CureMatch scores and ranks Personalized Combination Therapy® options to target specific molecular aberrations in cost-effective PreciGENE reports. This actionable intelligence guides oncologists to effectively customize treatment for each individual patient. Based in San Diego, CA, the CureMatch technology has expert foundation in supercomputing, oncology, genetics, proteomics, biochemistry, and cell biology. For more information, visit www.curematch.com

Media Contact
Name: Larissa Anderson
Company: CureMatch
Phone: 858-859-2873
Email: press@curematch.com

Share

  • LinkedIn
  • Facebook
  • Twitter
  • Reddit
  • Email
  • Print

Receive CureMatch News

Sign up for personalized oncology information and resources.
* = required field

Recent News & Resources

  • Launch of CureMatch Certified Precision Oncology Recognition Award

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

  • The Complex Cancer Puzzle | Video 1

    ShareLinkedInFacebookTwitterRedditEmailPrint

  • CureMatch and Mprobe Partner to Help Cancer Patients Determine Optimal Treatments

    CureMatch will leverage mProbe’s targeted proteomics platform to assess individual proteins within patients’ tumor tissues....

  • CureMatch Granted CPT® Code by American Medical Association for its Algorithmic Cancer Therapy Ranking Service

    Oncologists will be able to submit claims to payers using a Category III CPT code,...

  • CureMatch CEO Navid Alipour named a Top 50 Honoree Leader of Influence in Life Science by San Diego Business Journal

    Congratulations to CureMatch CEO Navid Alipour for being named a Top Leader of Influence in...

Validation

  • Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study

    Malignancies are molecularly complex and become more resistant with each line of...

  • Significance of Scores Generated by a Cancer Therapy Matching Engine for Patient Outcomes

    Oncologists need effective precision medicine tools to navigate the myriad of therapeutic...

  • Real-world Data from a Molecular Tumor Board Demonstrates Improved Outcomes with a Precision N-of-One Strategy

    Next-generation sequencing (NGS) has allowed the identification of novel potential targets for...

  • The Crossroads of Precision Medicine and Therapeutic Decision-Making: Use of an Analytical Computational Platform to Predict Response to Cancer Treatments

    Oncology is currently the largest area of clinical health expenditures for prescription...

Archives

  • May 2024 (1)
  • October 2023 (1)
  • June 2023 (1)
  • May 2023 (1)
  • March 2023 (1)
  • January 2023 (1)
  • July 2022 (2)
  • June 2022 (2)
  • April 2022 (1)
  • March 2022 (1)
  • February 2022 (3)
  • November 2021 (1)
  • October 2021 (2)
  • August 2021 (2)
  • July 2021 (1)
  • June 2021 (4)
  • May 2021 (1)
  • April 2021 (2)
  • March 2021 (1)
  • December 2020 (2)
  • October 2020 (3)
  • April 2020 (1)
  • November 2019 (2)
  • September 2019 (1)
  • August 2019 (1)
  • July 2019 (2)
  • April 2019 (1)
  • March 2019 (2)
  • September 2018 (1)
  • August 2018 (1)
  • July 2018 (1)
  • June 2018 (5)
  • May 2018 (1)
  • April 2018 (4)
  • March 2018 (1)
  • February 2018 (3)
  • January 2018 (4)
  • December 2017 (3)
  • November 2017 (1)
  • October 2017 (1)
  • September 2017 (3)
  • August 2017 (4)
  • June 2017 (6)
  • May 2017 (9)
  • April 2017 (11)
  • March 2017 (8)
  • February 2017 (3)
  • January 2017 (5)
  • October 2016 (1)
  • September 2016 (5)
  • August 2016 (2)
  • May 2016 (1)
  • April 2016 (1)

logo

+1 (858) 215-1313

Quick Links

  • Home
  • Physicians
  • About CureMatch
  • News and Latest Posts
  • Contact Us
  • FAQ

Latest News and Results

  • Launch of CureMatch Certified Precision Oncology Recognition Award May 8

    CureMatch, a leader in precision oncology, is proud to announce the establishment of the CureMatch...

  • CureMatch Announces Collaboration with Mark Cuban Cost Plus Drug Company to Promote Affordable Cancer Treatment Oct 7

    CureMatch, Inc., a healthcare technology company using precision medicine support for oncology, is proud to...

  • CureMatch Joins CancerX to Help Advance Innovative Cancer Treatments Jun 28

    CureMatch, Inc., a healthcare technology company leveraging Knowledge Representation & Reasoning (KRR) AI for precision...

© 2025 CureMatch, Inc. CureMatch is a registered trademark.
Terms of Use | Privacy Policy | HIPAA Notice

Please fill out the information below and a CureMatch representative will reach out to you.

 

Physician Request

  • This field is for validation purposes and should be left unchanged.

 

We value and respect your privacy and will not publish, share, or sell your contact information.

View Privacy Policy

Some pages of this website are intended for healthcare professionals

This webpage is strictly reserved for healthcare professionals. Please confirm that you are a healthcare professional.

Otherwise, you will be redirected to the institutional part of this website.

Thank you for your understanding.

I am a healthcare professionalI am not a healthcare professional

Get ready to utilize the latest genomics data in your practice

Rank the most promising systemic therapies for your patients

Do you need to filter out those therapies with poor outcomes

Sort through 4.5 million expertly curated combinations of drugs

Compute your own drug choices alongside CureMatch data